Ignite Creation Date:
2025-12-24 @ 5:43 PM
Ignite Modification Date:
2025-12-29 @ 6:28 AM
Study NCT ID:
NCT06808568
Status:
AVAILABLE
Last Update Posted:
2025-02-05
First Post:
2025-01-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access Program (EAP) STIMULAN VG
Sponsor:
Biocomposites Ltd
Organization:
Study Overview
Official Title:
Expanded Access Program (EAP) STIMULAN VG
Status:
AVAILABLE
Status Verified Date:
2025-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EAPSTIMVG
Brief Summary:
Individual (single) patient expanded access may be considered.
Detailed Description:
Patients facing serious or life-threatening illnesses who have exhausted currently available treatment options and are ineligible or unable to participate in a clinical trial may decide to explore therapeutic use of investigational drugs with their healthcare providers.
Under these circumstances, single-patient access can be requested from a licensed treating physician on behalf of the patient.
Please contact expandedaccess@biocomposites.com for more information.
Under these circumstances, single-patient access can be requested from a licensed treating physician on behalf of the patient.
Please contact expandedaccess@biocomposites.com for more information.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: